Lung cancer and HIV infection;Cancer du poumon et infection par le Virus de lĝ€™ Immunodéficience Humaine

Revue des Maladies Respiratoires

Volumn 31, Issue 2, 2014, Pages 133-141

  Lavole A ^a,b   Toper, C ^a   Belmont, L ^a,b   Ruppert, A M ^a,b   Wislez, M ^a,b   Cadranel, J ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Humanimmunodeficiencyvirus infection; Interactions cytotoxicchemotherapy andantiretroviraltreatment; Lung cancer

Indexed keywords

ARTICLE; CANCER PROGNOSIS; COMORBIDITY; DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG CANCER; RISK FACTOR; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CARCINOMA, NON-SMALL-CELL LUNG; COMPLICATION; COMPUTER ASSISTED TOMOGRAPHY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; LUNG NEOPLASMS; THORAX RADIOGRAPHY; VIROLOGY;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; CARCINOMA, NON-SMALL-CELL LUNG; HIV INFECTIONS; HIV-1; HUMANS; LUNG NEOPLASMS; RADIOGRAPHY, THORACIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84900825819     PISSN: 07618425     EISSN: 17762588     Source Type: Journal    
DOI: 10.1016/j.rmr.2013.07.009     Document Type: Review

References (49)

1. Mocroft A, Brettle R, Kirk O, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the Euro SIDA study. Aids 2002;16:1663-71.
2. Bonnet F, Lewden C, May T, et al. Malignancy-related causesof death in human immunodeficiency virus-infected patientsin the era of highly active antiretroviral therapy. Cancer 2004;101:317-24.
3. Bonnet F, Morlat P. Cancers et infection par le VIH : quellesassociations ? Rev Med Interne 2006;27:227-35.
4. Morlat P, Roussillon C, Hénard S, et al. Evolution of the Causesof Death among HIV+ Patients between 2000 and 2010: resultsof the French National Survey ''ANRS EN20 Mortalité 2010''.Abstract 1130 CROI; 2012.
5. Lanoy E, Spano J-P, Bonnet F, et al. The spectrum of malignan-cies in HIV-infected patients in 2006 in France: the ONCOVIH study. Int J Cancer 2011;129:467-75.
6. Engels EA, Brock MV, Chen J, et al. Elevated incidence oflung cancer among HIV-infected individuals. J Clin Oncol 2006;24:1383-8.
7. Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in theHIV-infected population in the United States. J Natl Cancer Inst 2011;103:753-62.
8. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer riskamong people with AIDS in the United States 1980-2002. Aids 2006;20:1645-54.
9. Grulich AE, van Leeuwen MT, Falster MO, et al. Incidenceof cancers in people with HIV/AIDS compared with immu-nosuppressed transplant recipients: a meta-analysis. Lancet 2007;370:59-67.
10. Spano JP, Costagliola D, Katlama C, et al. AIDS-related mali-gnancies: state of the art and therapeutic challenges. J Clin Oncol 2008;26:4834-42.
11. Bruyand M, Thiébaut R, Lawson-Ayayi S, et al. Role of uncon-trolled HIV RNA level and immunodeficiency in the occurrenceof malignancy in HIV-infected patients during the combina-tion antiretroviral therapy era: Agence Nationale de Recherchesur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis 2009;49:1109-16.
12. Bedimo R, Chen RY, Accortt NA, et al. Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002. Clin Infect Dis 2004;39:1380-4.
13. Grulich AE, Wan X, Law MG, et al. Risk of cancer in people with AIDS. Aids 1999;13:839-43.
14. Frisch M, Biggar RJ, Engels EA, et al. Association of can-cer with AIDS-related immunosuppression in adults. JAMA 2001;285:1736-45.
15. Gallagher B, Wang Z, Schymura MJ, et al. Cancer incidence inNew York State acquired immunodeficiency syndrome patients.Am J Epidemiol 2001;154:544-56.
16. Bower M, Powles T, Nelson M, et al. HIV-related lung can-cer in the era of highly active antiretroviral therapy. Aids 2003;17:371-5.
17. Herida M, Mary-Krause M, Kaphan R, et al. Incidence of non-AIDS-defining cancers before and during the highly activeantiretroviral therapy era in a cohort of human immunodefi-ciency virus-infected patients. J Clin Oncol 2003;21:3447-53.
18. Mbulaiteye SM, Biggar RJ, Goedert JJ, et al. Immune deficiencyand risk for malignancy among persons with AIDS. J AcquirImmune Defic Syndr 2003;32:527-33.
19. Dal Maso L, Franceschi S, Polesel J, et al. Risk of can-cer in persons with AIDS in Italy, 1985-1998. Br J Cancer 2003;89:94-100.
20. Shiels MS, Cole SR, Kirk GD, et al. A meta-analysis of the inci-dence of non-AIDS cancers in HIV-infected individuals. J AcquirImmune Defic Syndr 2009;52:611-22.
21. Saves M, Chene G, Ducimetiere P, et al. Risk factorsfor coronary heart disease in patients treated for humanimmunodeficiency virus infection compared with the generalpopulation. Clin Infect Dis 2003;37:292-8.
22. Parker MS, Leveno DM, Campbell TJ, et al. AIDS-related bron-chogenic carcinoma: fact or fiction? Chest 1998;113:154-61.
23. Chaturvedi AK, Pfeiffer RM, Chang L, et al. Elevated risk of lungcancer among people with AIDS. Aids 2007;21:207-13.
24. Kirk GD, Merlo C, O' Driscoll P, et al. HIV infection is associatedwith an increased risk for lung cancer, independent of smoking.Clin Infect Dis 2007;45:103-10.
25. Sigel K, Wisnivesky J, Gordon K, et al. HIV as an independentrisk factor for incident lung cancer. AIDS 2012;26:1017-25.
26. Reekie J, Kosa C, Engsig F, et al. Relationship between currentlevel of immunodeficiency and non-acquired immunodeficiencysyndrome-defining malignancies. Cancer 2010;116:5306-15.
27. Guiguet M, Boué F, Cadranel J, et al. Effect of immunodefi-ciency, HIV viral load, and antiretroviral therapy on the riskof individual malignancies (FHDH-ANRS CO4): a prospectivecohort study. Lancet Oncol 2009;10:1152-9.
28. Hader SL, Smith DK, Moore JS, et al. HIV infection inwomen in the United States: status at the Millennium. JAMA 2001;285:1186-92.
29. Hakimian R, Fang H, Thomas L, et al. Lung cancer in HIV-infected patients in the era of highly active antiretroviraltherapy. J Thorac Oncol 2007;2:268-72.
30. Lavolé A, Chouaïd C, Baudrin L, et al. Effect of highlyactive antiretroviral therapy on survival of HIV infectedpatients with non-small-cell lung cancer. Lung Cancer 2009;65:345-50.
31. Makinson A, Tenon JC, Eymard-Duvernay S, et al. Humanimmunodeficiency virus infection and non-small cell lung can-cer: survival and toxicity of antineoplastic chemotherapy in acohort study. J Thorac Oncol 2011;6:1022-9.
32. Pakkala S, Chen Z, Rimland D, et al. Human immunodeficiencyvirus- associated lung cancer in the era of highly active antire-troviral therapy. Cancer 2012;118:164-72.
33. Brock MV, Hooker CM, Engels EA, et al. Delayed diagnosis andelevated mortality in an urban population with HIV and lungcancer: implications for patient care. J Acquir Immune DeficSyndr 2006;43:47-55.
34. D'Jaen GA, Pantanowitz L, Bower M, et al. Human immuno-deficiency virus-associated primary lung cancer in the era ofhighly active antiretroviral therapy: a multi-institutional col-laboration. Clin Lung Cancer 2010;11:396-404.
35. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 2003;123:21S-49S.
36. Okuma Y, Yanagisawa N, Takagi Y, et al. Clinical characteristicsof Japanese lung cancer patients with human immunodefi-ciency virus infection. Int J Clin Oncol 2012;17:462-9.
37. Alshafie MT, Donaldson B, Oluwole SF. Human immunodeficiencyvirus and lung cancer. Br J Surg 1997;84:1068-71.
38. Sridhar KS, Flores MR, Raub WA, et al. Lung cancer in patientswith human immunodeficiency virus infection compared withhistoric control subjects. Chest 1992;102:1704-8.
39. Vyzula R, Remick SC. Lung cancer in patients with HIV-infection. Lung Cancer 1996;15:325-39.
40. Tirelli U, Spina M, Sandri S, et al. Lung carcinoma in 36 patientswith human immunodeficiency virus infection. The Italian Cooperative Group on AIDS and Tumors. Cancer 2000;88:563-9.
41. Tammemagi CM, Neslund-Dudas C, Simoff M, et al. Impactof comorbidity on lung cancer survival. In J Cancer 2003;103:792-802.
42. Spano JP, Massiani MA, Bentata M, et al. Lung cancer in patientswith HIV infection and review of the literature. Med Oncol 2004;21:109-15.
43. Lavole A, Massiani MA, Wislez M. Lung cancer in HIV-infectedpatients in the era of HAART: a case control study focusing onprognostic factors of survival. Lung cancer 2003;41:S3-314.
44. Biggar RJ, Engels EA, Ly S, et al. Survival after cancer diag-nosis in persons with AIDS. J Acquir Immune Defic Syndr 2005;39:293-9.
45. Powles T, Thirwell C, Newsom-Davis T, et al. Does HIV adverselyinfluence the outcome in advanced non-small-cell lung cancerin the era of HAART? Br J Cancer 2003;89:457-9.
46. Kivisto KT, Kroemer HK, Eichelbaum M. The role of humancytochrome P450 enzymes in the metabolism of anticanceragents: implications for drug interactions. Br J Clin Pharmacol 1995;40:523-30.
47. Makinson A, Pujol J-L, Le Moing V, et al. Interactions betweencytotoxic chemotherapy and antiretroviral treatment in humanimmunodeficiency virus-infected patients with lung cancer. JThorac Oncol 2010;5:562-71.
48. Powles T, Imami N, Nelson M, et al. Effects of combina-tion chemotherapy and highly active antiretroviral therapyon immune parameters in HIV-1 associated lymphoma. AIDS 2002;16:531-6.
49. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancermortality with low-dose computed tomographic screening. NEngl J Med 2011;365:395-409.